DDInter1281 DDInter782
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Neratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Colchicine
Neratinib may lead to a major life threatening interaction when taken with Fedratinib